The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells

By Arun Banu   Akar Ugur   Gutierrez-Barrera Angelica M.   Hortobagyi Gabriel N.   Ozpolat Bulent  

International Journal of Oncology, Vol. 47, Iss. 1, 2015-07 ,pp. : 262-268

Spandidos Publications

Access to resources Recommend Favorite

Effects of bafilomycin A1, a vacuolar type H + ATPase inhibitor, on the thermosensitivity of a human pancreatic cancer cell line

By Hayashi Yasuo   Katayama Kanji   Togawa Tamotsu   Kimura Toshihisa   Yamaguchi Akio  

International Journal of Hyperthermia, Vol. 22, Iss. 4, 2006-06 ,pp. : 275-285

Informa Healthcare

Access to resources Recommend Favorite

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib

By Daemen Anneleen  

Breast Cancer Research and Treatment, Vol. 135, Iss. 2, 2012-09 ,pp. : 505-517

Springer Publishing Company

Access to resources Recommend Favorite

High collagenolytic activity in spontaneously highly metastatic variants derived from a human pancreatic cancer cell line (SUIT-2) in nude mice

By Kitamura Norio   Iwamura Takeshi   Taniguchi Shoji   Yamanari Hideo   Kawano Kikuo   Hollingsworth Michael   Setoguchi Toshiaki  

Clinical and Experimental Metastasis, Vol. 18, Iss. 7, 2000-11 ,pp. : 561-571

Springer Publishing Company

Access to resources Recommend Favorite

PARP Inhibitor Development for Systemic Cancer Targeting

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 7, Iss. 5, 2007-09 ,pp. : 515-523

Bentham Science Publishers

Access to resources Recommend Favorite